Please Wait
Applying Filters...
menu
    • menu
    Evonik

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-01-12

    Virtual Booth

    An Enquiry

    End-to-end drug development, specializing in high-potency softgels and liquids, providing global partners with a competitive advantage.

    Virtual Booth

    Contact Supplier

    Kewpie is your partner for Sodium Hyaluronate & Hyaluronic Acid// CEP, USDMF, KDMF & JDMF registered.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    An Enquiry

    Menu

    Plinabulin

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Beyondspring Presents Plinabulin + Docetaxel Data At ESMO Asia
    Beyondspring Presents Plinabulin + Docetaxel Data At ESMO Asia

    12 Dec 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/12/12/3204554/0/en/BeyondSpring-Announces-ESMO-Asia-Presentation-on-Plinabulin-Docetaxel-Improving-Survival-in-Large-Phase-3-DUBLIN-3-Asian-Subset-for-EGFR-WT-NSCLC-Compared-to-Docetaxel-Strengthenin.html

    GLOBENEWSWIRE
    12 Dec 2025
    Share Share
    Beyondspring Reveals Ph3 of Plinabulin+Docetaxel Survival Benefit
    Beyondspring Reveals Ph3 of Plinabulin+Docetaxel Survival Benefit

    11 Dec 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/12/11/3203772/0/en/BeyondSpring-Announces-New-Analyses-of-DUBLIN-3-Phase-3-Study-Showing-Survival-Benefit-of-Plinabulin-Docetaxel-in-Post-Anti-PD-L-1-for-Non-squamous-EGFR-WT-NSCLC-and-a-Reduction-in.html

    GLOBENEWSWIRE
    11 Dec 2025
    Share Share
    BeyondSpring's Plinabulin Drives Dendritic Cell Maturation
    BeyondSpring's Plinabulin Drives Dendritic Cell Maturation

    07 Jul 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/07/07/3110902/0/en/BeyondSpring-Publishes-Human-Clinical-Study-in-Med-Cell-Press-Showing-Plinabulin-Driven-Dendritic-Cell-Maturation-and-Tumor-Response-After-Prior-Checkpoint-Inhibitor-Failure.html

    GLOBENEWSWIRE
    07 Jul 2025
    Share Share
    BeyondSpring Presents Data on Pembrolizumab Combo in NSCLC
    BeyondSpring Presents Data on Pembrolizumab Combo in NSCLC

    03 Jun 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/06/03/3092584/0/en/BeyondSpring-Presents-Efficacy-Safety-Data-from-a-Phase-2-Study-of-Pembrolizumab-plus-Plinabulin-Docetaxel-in-Metastatic-NSCLC-after-Progressing-on-First-Line-Immune-Checkpoint-Inh.html

    GLOBENEWSWIRE
    03 Jun 2025
    Share Share
    BeyondSpring Reports 2024 Financial Results & Key Milestones
    BeyondSpring Reports 2024 Financial Results & Key Milestones

    27 Mar 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/03/27/3050401/0/en/BeyondSpring-Reports-2024-Year-End-Financial-Results-and-Highlights-Key-Clinical-Strategic-Milestones.html

    GLOBENEWSWIRE
    27 Mar 2025
    Share Share
    BeyondSpring Sells 35.4M SEED Stake To Advance Plinabulin In Cancer
    BeyondSpring Sells 35.4M SEED Stake To Advance Plinabulin In Cancer

    28 Jan 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/01/28/3016236/0/en/BeyondSpring-Announces-35-4-Million-Sale-of-a-Portion-of-Equity-Interest-in-SEED-Therapeutics-to-Advance-Lead-Asset-Plinabulin-to-Anti-Cancer-Registrational-Studies.html

    GLOBENEWSWIRE
    28 Jan 2025
    Share Share
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.